BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 2018;33:635-45. [PMID: 29106598 DOI: 10.1093/ndt/gfx196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Haninger-Vacariu N, Herkner H, Lorenz M, Säemann M, Vychytil A, Jansen M, Marculescu R, Kramar R, Sunder-Plassmann G, Schmidt A. Exclusion of pregnancy in dialysis patients: diagnostic performance of human chorionic gonadotropin. BMC Nephrol 2020;21:70. [PMID: 32111190 DOI: 10.1186/s12882-020-01729-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Vinks AA, Peck RW, Neely M, Mould DR. Development and Implementation of Electronic Health Record–Integrated Model‐Informed Clinical Decision Support Tools for the Precision Dosing of Drugs. Clin Pharmacol Ther 2019;107:129-35. [DOI: 10.1002/cpt.1679] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
3 van Herpt TTW, Timmermans SAMEG, van Mook WNKA, van Bussel BCT, van der Horst ICC, Maessen JG, Natour E, van Paassen P, Heuts S. Postsurgical Thrombotic Microangiopathy and Deregulated Complement. JCM 2022;11:2501. [DOI: 10.3390/jcm11092501] [Reference Citation Analysis]
4 Ariceta G, Fakhouri F, Sartz L, Miller B, Nikolaou V, Cohen D, Siedlecki AM, Ardissino G. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clinical Kidney Journal 2021;14:2075-84. [DOI: 10.1093/ckj/sfab005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019;12:333-7. [PMID: 31198225 DOI: 10.1093/ckj/sfz040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
6 Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provôt F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Châtelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Frémeaux-Bacchi V. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 2021;137:2438-49. [PMID: 33270832 DOI: 10.1182/blood.2020009280] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, Yuan X, Sperati CJ, Moliterno AR, Brodsky RA. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv 2021;5:1504-12. [PMID: 33683339 DOI: 10.1182/bloodadvances.2020003175] [Reference Citation Analysis]
8 Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé Å, Minetti EE, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol 2019;20:125. [PMID: 30971227 DOI: 10.1186/s12882-019-1314-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
9 García-martín E, Manrique-rodríguez S, Martínez Fernández-llamazares C, Goicoechea-diezhondino M, Álvarez-blanco O, García-morín M, Sanjurjo-sáez M. Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2019;7:525-33. [DOI: 10.1080/21678707.2019.1703108] [Reference Citation Analysis]
10 Baskin E, Fidan K, Gulhan B, Gulleroglu K, Canpolat N, Yilmaz A, Parmakiz G, Ozcakar BZ, Ozaltin F, Soylemezoglu O. Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study. J Nephrol. [DOI: 10.1007/s40620-021-01212-w] [Reference Citation Analysis]
11 Knoop M, Haller H, Menne J. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment]. Internist (Berl) 2018;59:799-804. [PMID: 29995248 DOI: 10.1007/s00108-018-0455-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Yeter HH, Derici U, Arinsoy T, Altok K, Erten Y, Guz G. Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome. Rom J Intern Med 2021. [PMID: 34449174 DOI: 10.2478/rjim-2021-0034] [Reference Citation Analysis]
13 Kimman ML, Wijsenbeek MS, van Kuijk SMJ, Wijnsma KL, van de Kar NCAJ, Storm M, van Jaarsveld X, Dirksen CD; PESaM Collaborating Group. Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. Patient 2019;12:149-62. [PMID: 30367435 DOI: 10.1007/s40271-018-0340-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
14 Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol 2019;34:943-9. [PMID: 30693384 DOI: 10.1007/s00467-019-4192-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
15 McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard LP, Grewal K, Lapeyraque AL, Patriquin CJ, Pavenski K, Licht C. Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review. Can J Kidney Health Dis 2021;8:20543581211008707. [PMID: 33996107 DOI: 10.1177/20543581211008707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
17 Devresse A, de Meyer M, Aydin S, Dahan K, Kanaan N. De Novo Atypical Haemolytic Uremic Syndrome after Kidney Transplantation. Case Rep Nephrol 2018;2018:1727986. [PMID: 29732228 DOI: 10.1155/2018/1727986] [Reference Citation Analysis]
18 Bouwmeester RN, Ter Avest M, Wijnsma KL, Duineveld C, Ter Heine R, Volokhina EB, Van Den Heuvel LPWJ, Wetzels JFM, van de Kar NCAJ. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Front Immunol 2020;11:612706. [PMID: 33519821 DOI: 10.3389/fimmu.2020.612706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 Neave L, Gale DP, Cheesman S, Shah R, Scully M. Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy. Br J Haematol 2019;186:113-24. [PMID: 30916388 DOI: 10.1111/bjh.15899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]